Today: 7 February 2026
Subscribe
Browse Category

NYSE:NVO News 31 January 2026 - 6 February 2026

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly shares rose 3% Friday after the FDA chief warned of a crackdown on non-approved copycat weight-loss drugs. The rebound followed an 8% drop Thursday, triggered by news of a $49 compounded rival to Novo Nordisk’s Wegovy. Investors are watching Lilly’s 2026 outlook and the FDA’s April decision on its oral obesity drug. Fourth-quarter revenue jumped 43% to $19.3 billion, led by strong sales of Mounjaro and Zepbound.
6 February 2026
······
Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers Health shares fell 3.8% to $23.48 in premarket trading Friday after FDA Commissioner Marty Makary warned of a crackdown on “illegal copycat drugs.” The drop followed Hims’ launch of a $49 compounded version of Novo Nordisk’s Wegovy pill. Novo Nordisk said it would pursue legal and regulatory action, calling Hims’ move “illegal mass compounding.” Investors are watching for FDA enforcement and lawsuits ahead of Hims’ Feb. 23 report.
6 February 2026
······
Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Novo Nordisk shares fell 16% in Copenhagen after the company warned 2026 sales and profit may drop up to 13% due to falling U.S. drug prices and tougher competition. ADRs slid nearly 4% in New York. Novo plans a share buyback of up to 15 billion Danish crowns and named Jamey Millar as its new U.S. head. CEO Mike Doustdar said Wegovy price cuts have hit results but are meant to boost future demand.
4 February 2026
·····
Novo Nordisk stock price sinks nearly 18% as 2026 outlook jolts Wegovy trade

Novo Nordisk stock price sinks nearly 18% as 2026 outlook jolts Wegovy trade

Novo Nordisk shares fell about 18% in Copenhagen after the company warned of a possible 5–13% drop in 2026 sales and profit, citing U.S. price cuts and rising competition. The drugmaker faces pressure from cheaper copycat obesity drugs and a leadership change in its U.S. unit set for Feb. 5. U.S.-listed shares dropped 14.2% Tuesday.
4 February 2026
····
Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk warned adjusted sales and operating profit may fall 5% to 13% in 2026, citing U.S. price cuts and rising competition from Eli Lilly. Shares plunged 18% in early Copenhagen trading. CEO Mike Doustdar called the U.S. price reductions for Wegovy “painful.” Novo also flagged patent expiries and pressure from compounded GLP-1 drugs.
4 February 2026
·····
Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly shares fell 3.9% to $1,003.46 on Tuesday, tracking a sharp 14% drop in Novo Nordisk after its 2026 forecast signaled deeper pricing pressure in the obesity-drug market. Pfizer also slipped on new weight-loss drug data. Lilly will report quarterly results Wednesday, as investors watch for signs of further price cuts and shifting demand in the sector.
4 February 2026
·····
Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly shares fell 1.4% to $1,029.99 by midday Tuesday as U.S. prices for GLP-1 obesity drugs dropped sharply, prompting analysts to cut long-term forecasts. Novo Nordisk and Pfizer reported strong weight-loss data for rival drugs this week, intensifying competition. Investors await Lilly’s earnings update Wednesday for signals on pricing, demand, and supply outlooks.
3 February 2026
······
Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings

Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings

Eli Lilly shares rose 1.5% to close near $1,052.70 Monday, recovering from early losses ahead of its earnings report due Wednesday. Analysts have cut long-term forecasts for obesity drugs as prices fall and competition intensifies, with 2030 sales estimates for GLP-1 drugs dropping to about $100 billion. Investors are focused on Lilly’s pricing strategy and demand outlook. The FDA is set to rule on Lilly’s weight-loss pill by April 10.
2 February 2026
·····
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
··········
1 2 3 … 6

Stock Market Today

Blackstone (BX) stock price rebounds after Sabre deal as jobs, CPI loom next week

Blackstone (BX) stock price rebounds after Sabre deal as jobs, CPI loom next week

7 February 2026
New York, February 6, 2026, 21:13 EST — Market closed. Blackstone Inc. (BX) shares closed up 2.25% at $129.69 on Friday, after a sharp drop the day before and a bruising week for the sector. The stock was last at $129.65 in late after-hours trading. (StockAnalysis) The swing matters because Blackstone sits in the crosshairs of a wider rethink of private-market managers. Investors have been quick to punish anything tied to leverage, credit risk and tech exposure, then just as quick to buy back when rates and risk appetite settle. That push-pull has been driven in part by an AI-linked
Verizon stock price snaps 7-day run as consumer chief exit sharpens focus on turnaround

Verizon stock price snaps 7-day run as consumer chief exit sharpens focus on turnaround

7 February 2026
Verizon shares fell 1.7% to $46.31 Friday, ending a seven-session rally and closing about 2.7% below Thursday’s one-year high. The dip follows news that consumer chief Sowmyanarayan Sampath will step down, with Alfonso Villanueva named interim head. Verizon has climbed 16% since January 29 amid strong subscriber growth and a $25 billion buyback plan.
Cisco stock jumps 3% near $85 as UBS sticks with Buy ahead of Feb. 11 earnings

Cisco stock jumps 3% near $85 as UBS sticks with Buy ahead of Feb. 11 earnings

7 February 2026
Cisco shares rose 3% to $84.82 Friday, nearing $85 ahead of fiscal Q2 results due Feb. 11. UBS maintained a Buy rating and $90 target, citing strong product order growth and data-center demand. Investors are watching AI-related spending and U.S. economic data that could affect rates. Peers Fortinet, CrowdStrike, and Palo Alto Networks also gained.
Go toTop